Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-10-28

Clinical Trial Update: The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating thalidomide for suppressing systemic inflammatory response syndrome in hemodialysis patients was terminated, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Thalomid (thalidomide)

Snippet

Sponsor: George A. Kaysen, M.D. | Conditions: Hypoalbuminemia | Phase 3 | Status: TERMINATED | Results posted: 2016-10-28